电科投资党委书记、总经理靳彦彬近日接受上海证券报记者专访，解码了这家央企投资平台如何以耐心 资本链接战略与产业，为科技自立自强注入资本动力。 ◎记者 李雁争 在新一轮科技革命与产业变革交织演进的当下，央企资本正以战略力量引领产业升级，成为培育新质生 产力的重要引擎。电科投资作为中国电子科技集团有限公司（简称"中国电科"）唯一的资本投资运营平 台，从财务投资向战略投资的转型历程，勾勒出央企投资平台的发展新路径，也彰显了国家战略科技力 量在资本赋能产业中的使命担当。 电科投资党委书记、总经理靳彦彬近日接受上海证券报记者专访，解码了这家央企投资平台如何以耐心 资本链接战略与产业，为科技自立自强注入资本动力。 从财务投资到战略赋能的转型 提及电科投资的发展历程，靳彦彬介绍："2014年成立至今，我们用10年时间完成了三次跨越式发展， 从最初10亿元总资产成长为超200亿元规模的战略投资平台，连续6年斩获集团经营业绩考核A级。"这 份成绩单的背后，是电科投资始终紧跟集团战略步伐的精准定位。 以耐心资本助力科技自立自强 谈及未来发展，靳彦彬明确了电科投资的目标——成为"一流央企投资公司"。他表示，这里的"一流"并 非单纯 ...

Group 1 - The company has existing strategic cooperation with state-owned assets in some of its power plants and coal mines [1] - The company plans to introduce strategic investments, including state-owned capital, to enhance its core competitiveness [1] - The company will align its strategies with national industrial policies and market developments [1]

战略投资者引入方面，10月30日，中科电气控股股东暨实际控制人余新、李爱武夫妇及其一致行动人， 以及股东罗新华、黄越华、黄雄军与凯博成都基金签订《股份转让协议》，拟通过协议转让方式向后者 转让合计3427.82万股无限售条件流通股，占公司总股本的5.001%，转让价格为23.34元/股，总价款(含 税)约8亿元。 近日，中科电气收到转让方转发的深交所《上市公司股份协议转让确认书》，确认所涉股份转让相关材 料合规。该确认书有效期为六个月，转让双方需按载明股份数量一次性办理过户登记。若交易顺利实 施，凯博成都基金将成为中科电气持股5%以上的重要股东。 值得关注的是，凯博成都基金主要出资人为两方：一是国资背景投资主体成都产业投资集团有限公司 (以下简称"成都产投")，二是锂电池行业头部企业中创新航科技集团股份有限公司。此前，中科电气披 露股份转让事项时同步公告与成都产投签署全面深化战略合作协议，成都产投将发挥资本、资源及产业 布局优势，赋能公司扩大产能、升级产线、完善材料产业布局，双方共同推进负极材料产业化项目落 地，包括优先在四川省内共建具有竞争力的负极材料生产基地，增强公司市场竞争力。由此可见，中科 电气引入战 ...

董事相信，收购该物业将带来显著的战略、营运及财务优势。买方过去15年一直租用该物业，并将其用 作包装区域，以支援其产品生产的工厂运作。该物业位于买方现有工厂旁边，使得此次收购具有高度协 同效应及营运效率。 拥有该物业能消除对业主的依赖，并避免租金上涨或租约不获续签的风险，从而提供长期稳定性。此举 亦能避免因迁往新址而产生的重大成本及营运中断。由于该地点已证实适合买方的业务运营，购入该物 业可确保员工、供应商及物流安排的连续性与便利。 财务方面，拥有该厂房可将经常性租金支出转化为有价资产并强化买方的资产负债表。买方亦能全面掌 控翻新、升级及未来扩展计划。此外，工业物业通常具有增值潜力，长期而言可带来潜在资本收益。总 体而言，该收购为一项战略投资，有助维持营运连续性并带来长期财务效益。 智通财经APP讯，飞霓控股(08480)发布公告，于2025年12月15日，买方Texstrip Manufacturing Sdn.Bhd. (本公司间接全资附属公司)与卖方Time IT IN E(Pantai Timur)Sdn.Bhd.(一名独立第三方)订立买卖协议， 买方同意购买而卖方同意出售该物业，总购买价为610万令 ...

责任编辑：山上 格隆汇12月12日丨天阳科技(300872.SZ)公布，为实现天阳宏业科技股份有限公司的战略布局，充分借 助专业机构的投资能力、优质资源和专业能力，为公司在战略层面持续良性发展提供优质项目储备，进 一步提升公司综合竞争力和整体价值，公司于2025年12月11日与吴狄杰、程蕾、杜小强、於采、赵庆 浩、陈铜、晏梓陆、冯卫、毛新革、北京金鑫国泰投资管理有限公司（简称"金鑫国泰"）、北京红马天 安投资有限公司（简称"红马天安"）签订了《青岛红马金鑫创业投资基金合伙企业（有限合伙）合伙协 议》，使用自有资金3,000万元投资入伙由红马天安管理的基金青岛红马金鑫创业投资基金合伙企业 （有限合伙）（简称"合伙企业"或"红马金鑫基金"）。本合伙企业主要投资于：（1）专项投资于天津 星恒量智创业投资合伙企业（有限合伙）；（2）闲置资金可投资于银行活期存款、央行票据、国债、 货币市场基金等中国证监会认可的现金管理工具。 股票频道更多独家策划、专家专栏，免费查阅>> ...

Core Viewpoint - The article discusses the strategic investment of Yan Jianya, a newly crowned billionaire from Shaanxi, who acquired an 8% stake in the A-share listed company Sanrenxing for 450 million yuan, marking a significant move in the capital market [5][12]. Group 1: Investment Details - Yan Jianya's acquisition of Sanrenxing is seen as a "bottom-fishing" strategy, as the company has faced declining performance, with revenue dropping from 5.65 billion yuan in 2022 to 4.21 billion yuan in 2024, and net profit falling from 740 million yuan to 120 million yuan during the same period [5][13]. - Following the transaction, the controlling shareholder's stake in Sanrenxing decreased from 53.88% to 45.88%, while Yan Jianya became the second-largest shareholder with over 5% ownership [12][13]. - The deal is characterized as an effort to optimize the company's equity structure and introduce a significant strategic investor, which is expected to enhance governance and market credibility for Sanrenxing [13][14]. Group 2: Strategic Implications - For Sanrenxing, Yan Jianya's involvement is anticipated to bring threefold value: governance improvement, resource synergy, and strategic empowerment, particularly in expanding into high-end manufacturing and military sectors [13][14]. - Yan Jianya's investment is also a strategic positioning move, as Sanrenxing's marketing network and data resources could synergize with his beauty and skincare business, Giant Biogene, enhancing brand building and market promotion [14][15]. - The collaboration between Yan Jianya and Sanrenxing has been developing over several years, with previous joint ventures and investments laying the groundwork for this deeper capital connection [15][16]. Group 3: Broader Context of Yan Jianya's Investments - Prior to the Sanrenxing investment, Yan Jianya's notable investment was the acquisition of a 100% stake in Siyi Industrial by Kid King, valued at 1.65 billion yuan, marking it as the largest personal care acquisition in China this year [18][19]. - Yan Jianya's family empire includes three listed companies: Giant Biogene, Triangle Defense, and Sanrenxing, showcasing a diversified portfolio across biotechnology, advanced manufacturing, and marketing services [24][25]. - The family's investment strategy emphasizes industrial synergy, with plans for further capital expansion and resource integration through their private equity platform, Sanyuan Capital, which focuses on aerospace, new materials, and advanced manufacturing [26][29].

Core Viewpoint - The company has decided to waive its preferential purchase rights for a 13.75% stake in its subsidiary, Hunan Qibin Optical Technology Co., Ltd., which is to be sold for 473 million yuan to China Orient Asset Management Co., Ltd. This transaction is classified as a related party transaction, and the company aims to introduce strategic partners to enhance the development of Qibin Optical and maximize overall value [1]. Group 1 - The company will transfer a 13.75% stake in Hunan Qibin Optical Technology Co., Ltd. for 473 million yuan [1]. - The transaction is a related party transaction, with the transferor being an enterprise controlled by the company's actual controller [1]. - The company states that waiving the preferential purchase rights is a prudent response to industry adjustments [1]. Group 2 - After the transaction, the company will remain the controlling shareholder of Qibin Optical, with its shareholding ratio unchanged [1].

Core Viewpoint - The company Medike (688079) has approved a capital increase for its subsidiary, Zhejiang Medike Optical Semiconductor Co., Ltd., by introducing a strategic investor, which is expected to enhance its financial strength and core competitiveness [1][2] Group 1: Capital Increase Details - The strategic investor, Zhejiang Fuzhe Shaoxin Integrated Circuit Industry Fund Partnership (Limited Partnership), will invest 200 million yuan at a pre-investment valuation of 2.18 billion yuan, acquiring an 8.40% stake in the subsidiary [1] - After the capital increase, Medike's ownership in the optical semiconductor company will decrease to 82.44%, while the stake of the Service Trade Innovation Development Guidance Fund (Limited Partnership) will drop to 9.16% [1] Group 2: Financial Performance - The projected revenue for Medike Optical Semiconductor Co., Ltd. in 2024 is 313 million yuan, with a net loss of 42.47 million yuan; for the first three quarters of 2025, the revenue is expected to be 264 million yuan, with a net loss of 65.77 million yuan [1] Group 3: Strategic Implications - The capital increase is aimed at meeting the capital needs for the main business operations of Medike Optical Semiconductor and is expected to create synergistic effects by pooling various advantageous resources [2] - The agreement includes provisions for potential share buybacks, allowing Medike to repurchase shares from the investor and existing shareholders within four years under certain conditions [2]

Core Viewpoint - Medike (688079.SH) plans to introduce a strategic investor through its subsidiary Zhejiang Medike Optical Semiconductor Co., Ltd., with an investment of 200 million RMB at a pre-investment valuation of 2.18 billion RMB [1] Group 1: Investment Details - The strategic investor, Zhejiang Fuzhe Shaoxin Integrated Circuit Industry Fund Partnership (Limited Partnership), will acquire an 8.40% stake in the optical semiconductor company after the capital increase [1] - The funds from this capital increase will primarily be used for the main business operations of the optical semiconductor company and other purposes agreed upon by the investor [1] Group 2: Strategic Implications - The introduction of the strategic investor is expected to enhance the financial strength of the optical semiconductor company, better meeting the capital needs for its business development [1] - This capital increase aims to aggregate various advantageous resources to create synergies, further improving the core competitiveness and sustainable development capabilities of the optical semiconductor company [1] - After the completion of the capital increase, Medike will remain the controlling shareholder of the optical semiconductor company, which will continue to be included in Medike's consolidated financial statements [1]

Core Points - Wanji Technology announced the introduction of strategic investor Wuhan High-tech Industry Investment Fund through a capital increase of 20 million yuan to enhance its laser radar business and market competitiveness [2] - The capital increase will raise Wuhan Wanji's registered capital from 71 million yuan to 75 million yuan, with Wanji Technology's shareholding decreasing from 84.51% to 80% [2][3] - Wuhan High-tech was established on June 24, 2022, with a registered capital of 2 billion yuan, primarily engaged in equity investment and asset management [3] - Wuhan Wanji, established on December 10, 2013, reported a revenue of 85.65 million yuan and a net loss of 108.11 million yuan for the fiscal year 2024 [3] - The valuation of Wuhan Wanji's total equity was assessed at 31 million yuan, with a significant increase of 562.20% [4] - The agreement includes clauses for priority liquidation and buyback rights, allowing Wuhan High-tech to request a buyback under certain conditions [4]